Research and Markets: US Personalized Cancer Genome Sequencing Market Outlook 2018 Report Out Now

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/xrf9nw/us_personalized) has announced the addition of the "US Personalized Cancer Genome Sequencing Market Outlook 2018" report to their offering.

The whole genome sequencing technology, over the past decade, has developed at an unprecedented rate. There has been a rapid progression from targeted gene sequencing to targeted whole genome sequencing coupled with bioinformatics based sequencing platforms to analyze the data and thereby impart personalized treatment to individuals. The Whole Genome Sequencing has proved to be a key to new breakthrough in fighting against cancer. The explosion of genomic data into personalized treatment of cancer is due to the development of new methods, and the exponential decline in cost of whole genome sequencing.

The report entitled US Personalized Cancer Genome Sequencing Market Outlook 2018 entails detailed study of current and future cancer prevalence and incidences across US. In addition, it provides an insight about the leading states with cancer incidences. Also covered is age wise statistics for cancer and comprehensive figures for cancer in males and females. Further, we have provided potential states for whole genome sequencing to help market players gauge maximum opportunity for growth. Besides, the report also provides potential customer base and the market's growth potential for personalized cancer WGS till 2018.

The said advanced technology has potential to revolutionize the field of medicine. The author has closely monitored the regulatory landscape related to sequencing which requires consideration of the authorities over genome based tests. It has been observed that whole genome sequencing services have been concurrently regulated by FDA, CDC and CMS. Further, the author has also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. Apart from this, a major hurdle is to persuade health insurers to reimburse for the cost of sequencing the genomes of individual.

Companies Mentioned:

-Ambry Genetics

-Beckman Coulter Genomics

-BGI Americas Corporation

-Cofactor Genomics

-Complete Genomics

-EdgeBio

-Expression Analysis

-Foundation Medicine

-Illumina

-SeqWright

For more information visit http://www.researchandmarkets.com/research/xrf9nw/us_personalized

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology